Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 1 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
HIF-2α(Endothelial PAS domain-containing protein 1) | 3 |
Target |
Mechanism HIF-2α inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date13 Aug 2021 |
Target |
Mechanism HIF-2α inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACSS2 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date27 Sep 2018 |
Sponsor / Collaborator |
Start Date02 May 2018 |
Sponsor / Collaborator |
Start Date23 Feb 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
PT-2385 ( HIF-2α ) | Renal Cell Carcinoma More | Phase 2 |
Belzutifan ( HIF-2α ) | Von Hippel-Lindau Disease More | Phase 2 |
PT-2567 ( HIF-2α ) | Pulmonary Arterial Hypertension More | Preclinical |
PT-1403 ( ACSS2 ) | Neoplasms More | Pending |
PT-2399 ( HIF ) | Neoplasms More | Pending |